We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

145 hedge funds and large institutions have $423M invested in Akebia Therapeutics in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 57 increasing their positions, 39 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,259% more call options, than puts

Call options by funds: $9M | Put options by funds: $662K

46% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 39

3% more capital invested

Capital invested by funds: $412M → $423M (+$11.3M)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

1.94% less ownership

Funds ownership: 77.36% → 75.42% (-1.9%)

5% less funds holding

Funds holding: 153 → 145 (-8)

29% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 28

Holders
145
Holders Change
-8
Holders Change %
-5.23%
% of All Funds
3.32%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
20
Increased
57
Reduced
39
Closed
28
Calls
$9M
Puts
$662K
Net Calls
+$8.34M
Net Calls Change
+$5.32M

Top Buyers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
+$11.4M
2
BlackRock
BlackRock
New York
+$7.18M
3
CLM
ClearBridge LLC (Maryland)
Maryland
+$4.95M
4
State Street
State Street
Massachusetts
+$4.31M
5
Citadel Advisors
Citadel Advisors
Florida
+$3.91M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$13.6M
2
Renaissance Technologies
Renaissance Technologies
New York
-$6.45M
3
Goldman Sachs
Goldman Sachs
New York
-$4.74M
4
LCM
Laurion Capital Management
New York
-$4.47M
5
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$3.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
SLG
26
Stanley-Laman Group
Pennsylvania
$3.41M +$271K +27,088 +9%
Bank of America
27
Bank of America
North Carolina
$3.16M +$559K +55,790 +21%
Goldman Sachs
28
Goldman Sachs
New York
$3.07M -$4.74M -473,478 -61%
JP Morgan Chase
29
JP Morgan Chase
New York
$2.96M +$253K +25,273 +9%
Jacobs Levy Equity Management
30
Jacobs Levy Equity Management
New Jersey
$2.76M +$1.93M +192,834 +231%
SIM
31
Spark Investment Management
New York
$2.75M -$264K -26,400 -9%
TCM
32
Tekla Capital Management
Massachusetts
$2.66M +$1.34M +133,763 +101%
Man Group
33
Man Group
United Kingdom
$2.24M +$228K +22,800 +11%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$2.14M +$141K +14,089 +7%
AIM
35
Alambic Investment Management
California
$2.06M +$656K +65,514 +47%
SCA
36
Secor Capital Advisors
New York
$1.76M +$1.07M +106,470 +153%
Los Angeles Capital Management
37
Los Angeles Capital Management
California
$1.69M +$1.04M +103,920 +158%
Deutsche Bank
38
Deutsche Bank
Germany
$1.62M -$2.99M -298,750 -65%
VRS
39
Virginia Retirement Systems
Virginia
$1.41M +$1.03M +102,600 +266%
MOACM
40
Mutual of America Capital Management
New York
$1.34M – – –
Massachusetts Financial Services
41
Massachusetts Financial Services
Massachusetts
$1.33M +$1.34M +133,598 New
UBS Group
42
UBS Group
Switzerland
$1.32M -$603K -60,229 -31%
Allianz Asset Management
43
Allianz Asset Management
Germany
$1.24M -$6.91K -690 -0.6%
Wells Fargo
44
Wells Fargo
California
$1.19M +$55.1K +5,507 +5%
TA
45
Teachers Advisors
New York
$1.14M +$339K +33,857 +42%
OAM
46
Oxford Asset Management
United Kingdom
$1.12M -$311K -31,048 -21%
Acadian Asset Management
47
Acadian Asset Management
Massachusetts
$1M -$2M -199,758 -66%
PAWC
48
P.A.W. Capital
Connecticut
$998K +$1M +100,000 New
Alyeska Investment Group
49
Alyeska Investment Group
Illinois
$975K -$47.1K -4,701 -5%
AIM
50
Assured Investment Management
New York
$947K +$368K +36,745 +63%
1
2
3 4 5

AKBA Hedge Fund Activity: Q2 2018 in Review

145 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2018, worth a combined $423M — up 2.8% from $412M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of AKBA and 20 opened new positions — a net loss of 8 holders — while 39 trimmed existing stakes and 57 added.

The largest buyer was Nantahala Capital Management, adding an estimated $11.4M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $13.6M sold.

  • 145 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2018, down from 153 in Q1 2018.
  • Funds reported $423M of Akebia Therapeutics stock for Q2 2018, up 2.8% quarter-over-quarter.
  • 20 funds opened new Akebia Therapeutics positions in Q2 2018 and 28 closed out, a net change of -8 holders.
  • The largest Akebia Therapeutics buyer in Q2 2018 was Nantahala Capital Management, an estimated $11.4M added.
  • The largest Akebia Therapeutics seller in Q2 2018 was EcoR1 Capital, an estimated $13.6M sold.

Based on aggregated 13F filings for Q2 2018.